Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.48 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121310 | 1.00 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL12436316 | 1.00 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL3624029 | 0.90 | CTSK (0.50) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL3656517 | 0.90 | CTSK (0.50) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL1318658 | 0.88 | FOLH1 (0.56) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL1324835 | 0.88 | FOLH1 (0.56) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2769978 | 0.88 | FOLH1 (0.56) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL15033871 | 0.88 | CTSK (0.46) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL14288950 | 0.88 | CTSK (0.46) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL31085224 | 0.88 | CTSK (0.48) | PPARAPPARGCTSKCTSSACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION | 2018-04-12 | — | — | US | disclosed |
| US-9802957-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PPARA 1370/4885PPARG 1515/4885CTSK 2765/4885 |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PPARA 1370/4885PPARG 1515/4885CTSK 2765/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PPARA 1370/4885PPARG 1515/4885CTSK 2765/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PPARA 1370/4885PPARG 1515/4885CTSK 2765/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | PPARA 1022/4885PPARG 2752/4885CTSK 3982/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | PPARA 1370/4885PPARG 1515/4885CTSK 2765/4885 |
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | PPARA 3453/4885PPARG 3514/4885CTSK 1824/4885 |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | PPARA 3453/4885PPARG 3514/4885CTSK 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.